Gynaecological Cancers

Programme description

The Gynaecology Unit at the Royal Marsden serves a population of 1.7 million and is also a tertiary referral centre for more complex cases or second opinions. Our Unit treats ovarian (including germ cell), endometrial, cervical, vaginal and vulval cancers. Management of these tumour types requires a multidisciplinary team approach, and the Gynaecology Unit’s clinical research programme reflects this. Dr Susana Banerjee, consultant medical oncologist, is Research Lead. The Unit works in partnership with the Institute of Cancer Research. The number of women undergoing treatment within the Unit, together with the clinical and laboratory research infrastructure has led to significant, pioneering work in gynaecological cancers impacting on patient management. Our interests include BRCA-associated ovarian cancers, PARP inhibitors, anti-angiogenic agents and the PI3K pathway. We have close collaborations with colleagues (Prof de Bono, Dr Udai Banerji and team) in the Drug Development Unit at Royal Marsden Sutton, so that there is a seamless transition of developing drugs in gynaecological cancers from Phase I trials.

Our clinical trials portfolio focuses on scientifically-driven trials and includes phase I/II to phase III trials. The Medical Gynaecological Oncology Team comprises clinical trials co-ordinators, data managers, research nurses and clinical fellows at the London and Surrey sites.

A 3-6 month clinical fellowship is an exciting opportunity to gain clinical experience in the management of gynaecological cancers in a world-leading centre. The Unit supports research interests of individual fellows and opportunities to be involved in translational research and clinical trials. Fellows will be based across the Royal Marsden Chelsea (London) and Sutton (Surrey) sites.